SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
RAPT Therapeutics, Inc. (Name of Issuer) |
Common Stock, $0.0001 par value per share (Title of Class of Securities) |
75382E109 (CUSIP Number) |
12/27/2024 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
Rule 13d-1(b) |
Rule 13d-1(c) |
Rule 13d-1(d) |
SCHEDULE 13G
|
CUSIP No. | 75382E109 |
1 | Names of Reporting Persons
TCG Crossover GP II, LLC | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
13,193,110.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
11 | Percent of class represented by amount in row (9)
9.99 % | ||||||||
12 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13G
|
CUSIP No. | 75382E109 |
1 | Names of Reporting Persons
TCG Crossover Fund II, L.P. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
13,193,110.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
11 | Percent of class represented by amount in row (9)
9.99 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
CUSIP No. | 75382E109 |
1 | Names of Reporting Persons
Chen Yu | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
13,193,110.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
11 | Percent of class represented by amount in row (9)
9.99 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
RAPT Therapeutics, Inc. | |
(b) | Address of issuer's principal executive offices:
561 Eccles Avenue, South San Francisco, CALIFORNIA, 94080. | |
Item 2. | ||
(a) | Name of person filing:
This joint statement on Schedule 13G is being filed by TCG Crossover Fund II, L.P. (TCG Crossover II), TCG Crossover GP II, LLC (TCG Crossover GP II and together with TCG Crossover II, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 99.1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein. | |
(b) | Address or principal business office or, if none, residence:
The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301. | |
(c) | Citizenship:
TCG Crossover GP II is a limited liability company organized under the laws of the State of Delaware. TCG Crossover II is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America. | |
(d) | Title of class of securities:
Common Stock, $0.0001 par value per share | |
(e) | CUSIP No.:
75382E109 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | |
(b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | |
(c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | |
(d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | |
(e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | |
(f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); | |
(g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); | |
(h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
(i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
(j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
(k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
See Row 9 of the cover page for each Reporting Person and the corresponding comments. | |
(b) | Percent of class:
See Row 11 of the cover page for each Reporting Person and the corresponding comments.
%
| |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
See Row 5 of the cover page for each Reporting Person and the corresponding comments. | ||
(ii) Shared power to vote or to direct the vote:
See Row 6 of the cover page for each Reporting Person and the corresponding comments. | ||
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of the cover page for each Reporting Person and the corresponding comments. | ||
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of the cover page for each Reporting Person and the corresponding comments. | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Under certain circumstances set forth in the limited partnership agreement of TCG Crossover II and the limited liability company agreement of TCG Crossover GP II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be. | ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
Exhibit Information
|
Material to be Filed as Exhibits.
Exhibit 1 - Joint Filing Agreement. |